About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 2NCT04453423

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

This study will compare maintenance therapy with anlotinib plus pemetrexed versus pemetrexed or anlotinib alone, in patients with Non-squamous Non-small cell lung cancer who have not progressed during...

Lead sponsor: The First Affiliated Hospital with Nanjing Medical University•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Renhua Guo, MD

CONTACT

025-68136360 rhguo@njmu.edu.cn

Sponsors

Lead Sponsor

The First Affiliated Hospital with Nanjing Medical University

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Age ≥ 18 years and ≤ 75, ECOG PS: 0\~1, estimated survival duration more than 3 months;
•2. Subjects with histologically or cytologically confirmed locally advanced and/or advanced Non-squamous NSCLC;
•3. Signed and dated informed consent;
•4. adequate hematological, liver and renal function

Exclusion Criteria

•1. prior chemotherapy or treatment with another systemic anti-cancer agent
•2. malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS
•3. evidence of tumor invading major blood vessels
•4. current or recent use of aspirin (\>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes
•5. history of haemoptysis \>/=grade 2
•6. clinically significant cardiovascular disease

Related studies

RECRUITINGPhase 3

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

NCT06416410 · Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer

TERMINATEDPhase 2

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

NCT04504916 · Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, and more

TERMINATEDPhase 2

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

NCT04524689 · Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

TERMINATEDPhase 2

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

NCT05849246 · Non-squamous Non-small-cell Lung Cancer

Not Yet RecruitingPhase 2

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

NCT06028633 · Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 1, 2020Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment90

Start dateJul 2020

Last updatedJul 1, 2020

Condition

Non-squamous Non-small-cell Lung Cancer

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions